Corporate News – Aura Biosciences
On Wednesday 21 November 2026, the share price of Aura Biosciences (AURA) closed 3.11 % higher than the previous trading day. At 03:14 AM Central European Time, the stock traded at approximately USD 6.56, reflecting a modest gain after a recent 1.1 % decline since the end of October. The company’s current market capitalisation stands at USD 632.6 million, derived from a circulating supply of 103.7 million shares.
Over the last 24 hours, AURA saw a trading volume of roughly USD 3.5 million, indicating a relatively thin but active market. Its simple moving average (SMA) for the past 200 days is USD 6.66, situating the current price slightly below the medium‑term trend. The most recent 52‑week high, USD 9.54, was recorded on 5 May 2026, while the low, USD 4.73, was reached on 20 January 2026, underscoring the volatility inherent in a company at the frontier of nanotechnology for cancer treatment.
Context within the Broader Sector
The performance of AURA can be better understood by comparing it to a selection of peer companies that have shown varying movements in the same 24‑hour window:
| Stock | 24‑hour change | Current price (USD) | Market cap (USD million) | P/E Ratio |
|---|---|---|---|---|
| Evolv (EVLV) | +0.48 % | 4.28 | 753.5 | – |
| Mitek (MITK) | +3.72 % | 17.53 | 754 | 34.02 |
| Fidus Investment (FDUS) | –2.21 % | 18.45 | 754.9 | 9.15 |
| Collegium Pharmaceutical (COLL) | –0.78 % | 23.26 | 755 | 16.37 |
| Gold Reserve (GDRZF) | +0.31 % | 5.10 | 758.1 | – |
While some peers such as Mitek and Gold Reserve posted modest gains, others like Fidus Investment experienced a noticeable decline. Aura Biosciences’ upward trajectory, though modest, aligns more closely with the broader market sentiment favoring companies engaged in innovative biotechnological solutions.
Company Overview
Aura Biosciences, Inc. is headquartered in Cambridge, United States, and specialises in the development of nanotechnology aimed at cancer treatment. The company’s core product line comprises nanoparticles engineered to mimic viral structures, thereby evading the immune system and delivering therapeutic agents directly to malignant tissues. This technology positions Aura Biosciences at the intersection of healthcare, biotechnology, and pharmaceuticals.
The company’s public trading occurs on the Nasdaq exchange, and further information may be obtained from its website at www.aurabiosciences.com .
This article is intended to provide an overview of recent trading activity and market context for Aura Biosciences.
